Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Alpha Mannosidosis Market Poised To Hit $39.41 Billion By 2030 With A 17% CAGR
The alpha mannosidosis market has experienced rapid expansion recently. Projections indicate it will expand from $17.87 billion in 2025 to reach $21 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 17.5%. Historically, this growth was influenced by factors such as underdeveloped diagnostic infrastructure, a lack of awareness regarding the disease, a dependence on traditional treatments, inconsistent treatment protocols, and limited investment in research and development.
The alpha mannosidosis market size is projected to experience substantial growth in the upcoming years. It is expected to reach $39.41 billion in 2030, with a compound annual growth rate (CAGR) of 17.0%. This expansion during the forecast period can be attributed to increased investment in gene therapies, a rising adoption of enzyme replacement therapies, the development of healthcare infrastructure, advancements in diagnostic technologies, and regulatory incentives for rare diseases. Key trends anticipated in the forecast period include early genetic screening programs, the development of orphan drugs, personalized enzyme replacement therapy, the expansion of rare disease clinics, and collaborative research initiatives.
Get A Free Sample Report With In-Depth Market Insights:
Alpha Mannosidosis Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The increasing need for precision medicine is projected to stimulate the expansion of the alpha mannosidosis market. Precision medicine, a customized healthcare strategy, takes into account distinct patient characteristics such as genetic makeup, environmental factors, and lifestyle choices to enhance treatment and preventative measures. The growing adoption of precision medicine stems from progress in genomic technologies and data analytics, facilitating a more precise detection of genetic variations and their consequences for health. Furthermore, a heightened desire for individualized treatment plans, coupled with an increasing recognition of the shortcomings of standardized approaches, has intensified focus on customized healthcare remedies. This approach to medicine aids in developing targeted therapies specifically designed for the genetic mutations and patient profiles linked to this uncommon condition. To illustrate, in February 2024, data from the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, indicated that in 2023, the FDA sanctioned 16 new personalized treatments for rare diseases, representing a notable rise from merely six approvals in 2022. Consequently, the escalating demand for precision medicine is fueling the expansion of the alpha mannosidosis market.
Alpha Mannosidosis Market Breakdown By Product Type And Application
The alpha mannosidosis market covered in this report is segmented –
1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Other Therapies
2) By Indication: Type I, Type II, Type III
3) By End-User: Hospitals, Speciality Clinics
Subsegments:
1) By Bone Marrow Transplant (BMT): Autologous BMT, Allogeneic BMT
2) By Enzyme Replacement Therapy (ERT): Recombinant Enzymes, Long-acting Enzyme Formulations
3) By Other Therapies: Symptomatic Treatments, Gene Therapy, Supportive Care
Alpha Mannosidosis Market Innovation Trends Shaping Future Development
Companies active in the alpha mannosidosis market are concentrating on developing enzyme replacement therapy for rare alpha-mannosidosis. This therapy helps diminish the build-up of mannose-rich oligosaccharides in various tissues and organs by providing exogenous alpha-mannosidase. Such accumulation is a hallmark of alpha-mannosidosis and contributes to its pathological effects. For example, in February 2023, Chiesi Global Rare Diseases, a US-based pharmaceutical company, launched Lamzede (velmanase alfa). This product is the first enzyme replacement therapy authorized in the United States for treating alpha-mannosidosis, a rare genetic disorder characterized by the absence of the alpha-mannosidase enzyme in the body, and its manifestations outside the central nervous system. Lamzede works to restore normal cellular activity in patients by mimicking the function of the human body’s alpha-mannosidase enzyme. Patients receive a 10 mg injection of Lamzede once a week.
Alpha Mannosidosis Market Company Landscape And Competitive Strategy
Major companies operating in the alpha mannosidosis market are Chiesi Farmaceutici S.p.A., Cipla, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Zymenex A/S, Albumedix Ltd, Freeline Therapeutics, Avectas, DiNAQOR AG, Vivet Therapeutics, Herantis Pharma Plc, PTC Therapeutics, Biocad, Sanofi, Orchard Therapeutics, Shire Pharmaceuticals, Amicus Therapeutics, BioMarin Pharmaceutical Inc, Genzyme
View The Full Alpha Mannosidosis Market Report:
Alpha Mannosidosis Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the alpha mannosidosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha mannosidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
